Soft tissue and bone malignancies that affect children and young adults frequently have a poor
prognosis and a limited set of therapeutic options. A better understanding of their molecular
pathogenesis would give us a chance to improve the treatment, by making it more specific and less
toxic than the generic chemo and radiotherapy. Recently, it has become clear that the chromatin
status of cancer cells is essential for the development of these malignancies but the study of the
epigenome remains technically difficult and frequently elusive. The purpose of this work is to help
overcome this difficulty by creating a set of tools tailored to study chromatin modifications and
their effect on tumor biology. In particular, the aim of our work is to adapt CRISPR-Cas9
technology, which has already revolutionized genome editing in the last decade, toward the study of
epigenetic events.